Jonathan Zalevsky, an officer of Nektar Therapeutics, filed a Form 144 notice on November 17, 2026, proposing to sell 192 shares of Nektar common stock on the NASDAQ exchange through Fidelity Brokerage Services LLC.

Key Highlights

  • Proposed sale: 192 shares of Nektar Therapeutics common stock with an aggregate market value of $6,882.68.
  • Source of shares: The shares were acquired on November 13, 2026, through restricted stock vesting from the issuer, classified as compensation.
  • Tax-related purpose: According to the filing, the sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution.
  • Prior sales: Zalevsky sold 186 shares of Nektar common stock on August 18, 2026, for gross proceeds of $13,387.96, as reported in the three-month sales history.
  • Outstanding shares: The filing states 34,214,683 shares of Nektar common stock were outstanding at the time of notice.
  • Broker: The proposed sale is to be executed through Fidelity Brokerage Services LLC, 900 Salem Street, Smithfield, RI 02917.

Zalevsky's Proposed Rule 144 Sale: Filing Details

Nektar Therapeutics (NASDAQ:NKTR), headquartered at 455 Mission Bay Boulevard South, San Francisco, California, is the issuer in this Form 144 notice. The filing identifies Jonathan Zalevsky as an officer of the company and as the person for whose account the 192 shares of common stock are proposed to be sold. The approximate date of sale listed in the filing is November 17, 2026.

According to the filing, the 192 shares subject to the proposed sale were acquired on November 13, 2026, through restricted stock vesting from the issuer. The nature of payment is listed as compensation. The filing notes in its remarks section that the sale "includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution," quoting the filing directly.

The filing also discloses Zalevsky's sales activity during the prior three months. A single prior transaction is listed: 186 shares of Nektar common stock sold on August 18, 2026, generating gross proceeds of $13,387.96. The Form 144 was signed by Jared Cook as a duly authorized representative of Fidelity Brokerage Services LLC, acting as attorney-in-fact for Jonathan Zalevsky, and dated November 17, 2026.

What Was Disclosed

Nektar Therapeutics officer Jonathan Zalevsky filed a Form 144 on November 17, 2026, proposing to sell 192 shares of common stock valued at $6,882.68, acquired through restricted stock vesting on November 13, 2026, with the stated purpose of covering a tax obligation from a vested equity award.